{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:03:43Z","timestamp":1792515823487,"version":"4.5.0"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"vor","delay-in-days":46,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.ctarc.2022.100537","type":"journal-article","created":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T12:15:53Z","timestamp":1645186553000},"page":"100537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Immunotherapy with GcMAF revisited - A critical overview of the research of Nobuto Yamamoto"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8493-8527","authenticated-orcid":false,"given":"Simon PJ","family":"Albracht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2022.100537_bib0001","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1593\/tlo.08106","article-title":"Immunotherapy for prostate cancer with Gc protein-derived macrophage-activating factor, GcMAF","volume":"1","author":"Yamamoto","year":"2008","journal-title":"Transl. Oncol"},{"key":"10.1016\/j.ctarc.2022.100537_bib0002","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00262-007-0431-z","article-title":"Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF","volume":"57","author":"Yamamoto","year":"2008","journal-title":"Cancer Immunol. Immunother"},{"key":"10.1016\/j.ctarc.2022.100537_bib0003","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/ijc.23107","article-title":"Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF)","author":"Yamamoto","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ctarc.2022.100537_bib0004","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jmv.21376","article-title":"Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF)","volume":"81","author":"Yamamoto","year":"2009","journal-title":"J. Med.Virol."},{"issue":"Suppl. 1","key":"10.1016\/j.ctarc.2022.100537_bib0005","article-title":"Immunotherapy of breast cancer with Gc protein-derived macrophage activating factor, GcMAF","volume":"71","author":"Yamamoto","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctarc.2022.100537_bib0006","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3483","article-title":"Alpha-N-acetylgalactosaminidase deficiency: Schindler disease,","author":"Desnick","year":"2001"},{"key":"10.1016\/j.ctarc.2022.100537_bib0007","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bbacli.2017.10.001","article-title":"Multiple exo-glycosidases in human serum as detected with the substrate DNP-a-GalNAc. I. A new assay for lysosomal a-N-acetylgalactosaminidase","volume":"8","author":"Albracht","year":"2017","journal-title":"BBA Clin"},{"key":"10.1016\/j.ctarc.2022.100537_bib0008","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bbacli.2017.09.002","article-title":"Multiple exo-glycosidases in human serum as detected with the substrate DNP-a-GalNAc. II. Three a-N-acetylgalactosaminidase-like activities in the pH 5 to 8 region","volume":"8","author":"Albracht","year":"2017","journal-title":"BBA Clin"},{"key":"10.1016\/j.ctarc.2022.100537_bib0009","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/00000658-197010000-00018","article-title":"Immunological factors in human sarcomas and melanomas: a rational basis for immunotherapy","volume":"172","author":"Morton","year":"1970","journal-title":"Ann. Surgery"},{"key":"10.1016\/j.ctarc.2022.100537_bib0010","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF00199146","article-title":"Activation of macrophages by ether analogues of lysophospholipids","volume":"25","author":"Yamamoto","year":"1987","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ctarc.2022.100537_bib0011","first-page":"2008","article-title":"Activation of mouse peritoneal macrophages by lysophospholipids and ether derivatives of neutral lipids and phospholipids","volume":"47","author":"Yamamoto","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctarc.2022.100537_bib0012","first-page":"6044","article-title":"Activation of mouse macrophages by alkylglycerols, inflammation products of cancerous tissues","volume":"48","author":"Yamamoto","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctarc.2022.100537_bib0013","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2249.1990.tb05195.x","article-title":"Activation process of macrophages after in vitro treatment of mouse lymphocytes with dodecylglycerol","volume":"79","author":"Homma","year":"1990","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ctarc.2022.100537_bib0014","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4049\/jimmunol.147.1.273","article-title":"Identification of the serum factor required for in vitro activation of macrophages","volume":"147","author":"Yamamoto","year":"1991","journal-title":"J Immunol"},{"key":"10.1016\/j.ctarc.2022.100537_bib0015","doi-asserted-by":"crossref","first-page":"8539","DOI":"10.1073\/pnas.88.19.8539","article-title":"Vitamin D3 binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes","volume":"88","author":"Yamamoto","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ctarc.2022.100537_bib0016","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/cbf.2835","article-title":"New perspectives on the vitamin D binding protein","volume":"30","author":"Chun","year":"2012","journal-title":"Cell. Biochem. Funct."},{"key":"10.1016\/j.ctarc.2022.100537_bib0017","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/185931b0","article-title":"Inheritance of a new group-specific system demonstrated in normal human sera by means of an immuno-electrophoretic technique","volume":"185","author":"Hirschfeld","year":"1960","journal-title":"Nature"},{"key":"10.1016\/j.ctarc.2022.100537_bib0018","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/0006-291X(83)91579-6","article-title":"Isolation and characterization of the O-glycan chain of the human vitamin-D binding protein","volume":"117","author":"Viau","year":"1983","journal-title":"Biochem. Biophys Res. Commun."},{"key":"10.1016\/j.ctarc.2022.100537_bib0019","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cca.2006.03.011","article-title":"Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism","volume":"372","author":"Speeckaert","year":"2006","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ctarc.2022.100537_bib0020","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1021\/pr8002936","article-title":"Population studies of vitamin D binding protein microheterogeneity by mass spectrometry lead to characterization of its genotype-dependent O-glycosylation patterns","volume":"7","author":"Borges","year":"2008","journal-title":"J. Proteom. Res."},{"key":"10.1016\/j.ctarc.2022.100537_bib0021","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1373\/clinchem.2011.176545","article-title":"Accuracy of 6 routine 25-hydroxyvitamin D assays: influence of vitamin D binding protein concentration","volume":"58","author":"Heijboer","year":"2012","journal-title":"Clinic. Chem."},{"key":"10.1016\/j.ctarc.2022.100537_bib0022","doi-asserted-by":"crossref","first-page":"5958","DOI":"10.1016\/S0021-9258(18)50505-6","article-title":"Human serum binding protein for vitamin D and its metabolites. I Physicochemical and immunological indentification in human tissues","volume":"254","author":"Cooke","year":"1979","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ctarc.2022.100537_bib0023","doi-asserted-by":"crossref","first-page":"5965","DOI":"10.1016\/S0021-9258(18)50506-8","article-title":"Human serum binding protein for vitamin D and its metabolites. II Specific, high affinity association with a protein in nucleated tissue","volume":"254","author":"Cooke","year":"1979","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ctarc.2022.100537_bib0024","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/S0021-9258(19)85885-4","article-title":"Vitamin D-binding protein (Gc-globulin) binds actin","volume":"255","author":"Van Baelen","year":"1980","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ctarc.2022.100537_bib0025","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1742-7843.2010.00587.x","article-title":"Safety pharmacology, toxicology and pharmacokinetic assessment of human Gc globulin (vitamin D binding protein), Basic","volume":"107","author":"Pihl","year":"2010","journal-title":"Clinic. Pharmacol. Toxicol."},{"key":"10.1016\/j.ctarc.2022.100537_bib0026","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/00365510701326909","article-title":"Comparison of rocket and crossed immuno-electrophoresis assays for determination of the level of actin complexing of Gc globulin","volume":"67","author":"J\u00f8rgensen","year":"2007","journal-title":"Scand. Clin. Lab. Invest."},{"key":"10.1016\/j.ctarc.2022.100537_bib0027","first-page":"131","article-title":"Gc-globulin in liver disease","volume":"55","author":"Schi\u00f8dt","year":"2008","journal-title":"Danisch Med. Bull."},{"key":"10.1016\/j.ctarc.2022.100537_bib0028","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0009-8981(85)90144-5","article-title":"Accurate quantitation of native Gc in serum and estimation of endogenous Gc:G-actin complexes by rocket immunoelectrophoresis","volume":"148","author":"Goldschmidt-Clermont","year":"1985","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ctarc.2022.100537_bib0029","first-page":"2827","article-title":"Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients","volume":"56","author":"Yamamoto","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctarc.2022.100537_bib0030","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0161-5890(96)00081-8","article-title":"Structural definition of a potent macrophage activating factor derived from vitamin D3-binding protein with adjuvant activity for antibody production","volume":"33","author":"Yamamoto","year":"1996","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ctarc.2022.100537_bib0031","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1002\/pro.214","article-title":"Glycosylation status of vitamin D binding protein in cancer patients","volume":"18","author":"Rehder","year":"2009","journal-title":"Prot. Sci."},{"key":"10.1016\/j.ctarc.2022.100537_bib0032","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.abb.2016.08.006","article-title":"Glycan structure of Gc Protein-derived Macrophage Activating Factor as revealed by mass spectrometry","volume":"606","author":"Borges","year":"2016","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ctarc.2022.100537_bib0033","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1440-1711.1998.00748.x","article-title":"Structurally well-defined macrophage activating factor derived from vitamin D3-binding protein has a potent adjuvant activity for immunization","volume":"76","author":"Yamamoto","year":"1998","journal-title":"Immunol. Cell. Biol."},{"key":"10.1016\/j.ctarc.2022.100537_bib0034","article-title":"Macrophage activating factors derived from cloned vitamin D binding protein","author":"Yamamoto","year":"1996","journal-title":"WIPO Patent Number WO 96\/40903 A1"},{"key":"10.1016\/j.ctarc.2022.100537_bib0035","first-page":"2187","article-title":"Immunotherapy of BALB\/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor","volume":"57","author":"Yamamoto","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctarc.2022.100537_bib0036","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0003-9861(02)00033-4","article-title":"Biochemical and preliminary crystallographic characterization of the vitamin D sterol- and actin-binding by human vitamin D-binding protein","volume":"402","author":"Swamy","year":"2002","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ctarc.2022.100537_bib0037","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nsb754","article-title":"A structural basis for the unique binding features of the human vitamin D-binding protein","volume":"9","author":"Verboven","year":"2002","journal-title":"Nature Struct. Biol."},{"issue":"002","key":"10.1016\/j.ctarc.2022.100537_bib0038","article-title":"In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor","volume":"177","author":"Yamamoto","year":"1993","journal-title":"Patent Number US 5"},{"key":"10.1016\/j.ctarc.2022.100537_bib0039","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/0003-2697(86)90624-X","article-title":"Purification of human serum vitamin D-binding protein by 25-hydroxyvitamin D3-Sepharose chromatography","volume":"157","author":"Link","year":"1986","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ctarc.2022.100537_bib0040","article-title":"Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis","volume":"6","author":"Yamamoto","year":"2002","journal-title":"Patent Number US"},{"key":"10.1016\/j.ctarc.2022.100537_bib0041","article-title":"Determination of alpha-N-acetylgalactosaminidase activity","author":"Yamamoto","year":"2003","journal-title":"Patent Number EP1340815 A2"},{"key":"10.1016\/j.ctarc.2022.100537_bib0042","unstructured":"N. Yamamoto, Diagnostic and prognostic ELISA assays of serum or plasma a-N-acetylgalactosamindase for cancer, Patent Number US 5,712,104 A, 1998."},{"key":"10.1016\/j.ctarc.2022.100537_bib0043","unstructured":"N. Yamamoto, Diagnostic and prognostic ELISA assays of serum a-N-acetylgalactosaminidase for AIDS, Patent Number US 5,985,545 A, 1999."},{"key":"10.1016\/j.ctarc.2022.100537_bib0044","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.micinf.2005.01.015","article-title":"Pathogenic significance of a-N-acetylgalactosaminidase activity found in the hemagglutinin of influenza virus","volume":"7","author":"Yamamoto","year":"2005","journal-title":"Microb. Infect."},{"key":"10.1016\/j.ctarc.2022.100537_bib0045","doi-asserted-by":"crossref","first-page":"21560","DOI":"10.1074\/jbc.M110.118588","article-title":"Interconversion of the specificities of human lysosomal enzymes associated with Fabry and Schindler diseases","volume":"285","author":"Tomasic","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ctarc.2022.100537_bib0046","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00262-014-1587-y","article-title":"Inconsistencies and questionable reliability of the publication ''Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophages-activating, GcMAF'' by Yamamoto et\u00a0al","volume":"63","author":"Ugarte","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ctarc.2022.100537_bib0047","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.bbapap.2009.12.022","article-title":"The glycosylation and characterization of the candidate Gc macrophage activating factor","volume":"1804","author":"Ravnsborg","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ctarc.2022.100537_bib0048","article-title":"Macrophage activating factor for pharmaceutical compositions","author":"Yamamoto","year":"2012","journal-title":"WIPO Patent Number WO 2012\/137199 Al"},{"key":"10.1016\/j.ctarc.2022.100537_bib0049","first-page":"2881","article-title":"Degalactosylated\/desialylated human serum containing GcMAF induces macrophage phagocytic activity and in vivo antitumor activity","volume":"33","author":"Kuchiike","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctarc.2022.100537_bib0050","first-page":"4577","article-title":"A novel assay system for macrophage-activating factor activity using a human U937 cell line","volume":"34","author":"Ishikawa","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctarc.2022.100537_bib0051","first-page":"4441","article-title":"Establishment of a macrophage-activating factor assay system using the human monocytic cell line THP-1","volume":"35","author":"Inoue","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctarc.2022.100537_bib0052","series-title":"Biological Chemistry","author":"Mahler","year":"1967"},{"key":"10.1016\/j.ctarc.2022.100537_bib0053","first-page":"334","article-title":"The inflammatory response to a foreign body within transplantable tumors","volume":"22","author":"Mahoney","year":"1962","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctarc.2022.100537_bib0054","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1089\/aid.1995.11.1373","article-title":"Structural modification of serum vitamin D3-binding protein and immunosuppression in AIDS patients","volume":"11","author":"Yamamoto","year":"1995","journal-title":"Aids Res. Hum. Retrovir."},{"key":"10.1016\/j.ctarc.2022.100537_bib0055","first-page":"213","article-title":"Origin of immunosuppression in juvenile leukemia and therapeutic efficacy of vitamin D3-binding protein-derived macrophage activating factor","volume":"37","author":"Naraparaju","year":"1996","journal-title":"Proc. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.ctarc.2022.100537_bib0056","first-page":"295","article-title":"Prognostic utility of serum a-N-acetylgalactosaminidase and immunosuppression resulted from deglycosylation of serum Gc protein in oral cancer patients","volume":"57","author":"Yamamoto","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctarc.2022.100537_bib0057","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/bjc.1998.166","article-title":"The value of serum a-N-acetylgalactosaminidase measurement for the assessment of tumour response to radio- and photodynamic therapy","volume":"77","author":"Korbelik","year":"1998","journal-title":"British J. Cancer"},{"key":"10.1016\/j.ctarc.2022.100537_bib0058","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1172\/JCI112185","article-title":"A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein","volume":"76","author":"Lilja","year":"1985","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ctarc.2022.100537_bib0059","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0090-4295(05)80066-4","article-title":"Prostate-specific antigen and prostate acid phosphatase: biomolecular and physiological characteristics","volume":"38","author":"Bilhartz","year":"1991","journal-title":"Urology"},{"key":"10.1016\/j.ctarc.2022.100537_bib0060","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1210\/er.2009-0034","article-title":"Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus","volume":"31","author":"Lawrence","year":"2010","journal-title":"Endocrine Rev"},{"key":"10.1016\/j.ctarc.2022.100537_bib0061","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/BF00185066","article-title":"Structure, function, and regulation of the enzyme activity of prostate-specific antigen","volume":"11","author":"Lilja","year":"1993","journal-title":"World J. Urol."},{"key":"10.1016\/j.ctarc.2022.100537_bib0062","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/(SICI)1097-0142(19960815)78:4<809::AID-CNCR18>3.0.CO;2-Z","article-title":"Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen","volume":"78","author":"Murphy","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2022.100537_bib0063","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1100\/tsw.2010.182","article-title":"PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer","volume":"10","author":"Tosoian","year":"2010","journal-title":"TheScientificWorldJOURNAL"},{"key":"10.1016\/j.ctarc.2022.100537_bib0064","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/BF00601924","article-title":"\u00dcber die Entstehung der Krebszellen","volume":"42","author":"Warburg","year":"1955","journal-title":"Naturwissensch"},{"key":"10.1016\/j.ctarc.2022.100537_bib0065","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1089\/aid.2006.22.262","article-title":"Pathogenic significance of a-N -acetylgalactosaminidase activity found in the envelope glycoprotein gp160 of human immunodeficiency virus type 1","volume":"22","author":"Yamamoto","year":"2006","journal-title":"Aids Res. Hum. Retrovir."},{"key":"10.1016\/j.ctarc.2022.100537_bib0066","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.antiviral.2013.04.013","article-title":"Viral envelope glycoprotein processing by proprotein convertases","volume":"99","author":"Pasquato","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ctarc.2022.100537_bib0067","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.1093\/nar\/25.24.4876","article-title":"The CLUSTAL X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools","volume":"25","author":"Thompson","year":"1997","journal-title":"Nucl. Acids Res."},{"key":"10.1016\/j.ctarc.2022.100537_bib0068","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.cell.2018.02.054","article-title":"Common features of enveloped viruses and implications for immunogen design for next-generation vaccines","volume":"172","author":"Rey","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ctarc.2022.100537_bib0069","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/jnci\/94.17.1311","article-title":"Effects of vitamin D3 -binding protein-derived macrophage activating factor (GcMAF) on angiogenesis","volume":"94","author":"Kanda","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ctarc.2022.100537_bib0070","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1084\/jem.20150295","article-title":"The interaction of anticancer therapies with tumor-associated macrophages","volume":"212","author":"Mantovani","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ctarc.2022.100537_bib0071","doi-asserted-by":"crossref","first-page":"48436","DOI":"10.18632\/oncotarget.17061","article-title":"Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy","volume":"8","author":"Zheng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctarc.2022.100537_bib0072","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/febs.14343","article-title":"The roles of CSFs on the functional polarization of tumor-associated macrophages","volume":"285","author":"Jeannin","year":"2017","journal-title":"FEBS J"},{"key":"10.1016\/j.ctarc.2022.100537_bib0073","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/febs.14395","article-title":"The inflammation \u2013 cancer connection","volume":"285","author":"Mantovani","year":"2018","journal-title":"FEBS J"},{"key":"10.1016\/j.ctarc.2022.100537_bib0074","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.3390\/ijms22083805","article-title":"& Tumor-associated macrophages and inflammatory microenvironment in gastric cancer: novel translational implications","volume":"22","author":"Rihawi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ctarc.2022.100537_bib0075","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/0022034509359125","article-title":"Factor affecting wound healing","volume":"83","author":"Guo","year":"2010","journal-title":"J. Dent. Res."},{"key":"10.1016\/j.ctarc.2022.100537_bib0076","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1055\/s-0039-1687908","article-title":"Tumors: wounds that do not heal - A historical perspective with a focus on the fundamental roles of increased vascular permeability and clotting","volume":"45","author":"Dvorak","year":"2019","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.ctarc.2022.100537_bib0077","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3389\/fimmu.2019.01084","article-title":"Macrophage polarization: different gene signatures in M1(LPS+) vs. classically and M2(LPS-) vs. alternatively activated macrophages","volume":"10","author":"Orecchioni","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ctarc.2022.100537_bib0078","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1021\/jm00334a044","article-title":"Substrates for cytochemical demonstration of enzyme activity. I. Some substituted 3-indolyl-b-D-glycopyranosides","volume":"7","author":"Horwitz","year":"1964","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ctarc.2022.100537_bib0079","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/10520290701375278","article-title":"Indigogenic substrates for detection and localization of enzymes","volume":"82","author":"Kiernan","year":"2007","journal-title":"Biotech. Histochem."},{"key":"10.1016\/j.ctarc.2022.100537_bib0080","first-page":"1135","article-title":"Cancer immune therapy in clinic: 2016","volume":"1","author":"Akiyama","year":"2016","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.ctarc.2022.100537_bib0081","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ctarc.2022.100537_bib0082","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.3390\/cancers12061449","article-title":"& Current strategies and novel therapeutic approaches for metastatic urothelial carcinoma","volume":"12","author":"Mollica","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctarc.2022.100537_bib0083","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Drug Discov"},{"key":"10.1016\/j.ctarc.2022.100537_bib0084","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.110293","article-title":"Potential role of GcMAF in suppressing the severity of COVID-19-induced immune responses: Lesson learned from HIV","volume":"144","author":"Spadera","year":"2020","journal-title":"Med. Hyp"},{"key":"10.1016\/j.ctarc.2022.100537_bib0085","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nature11287","article-title":"A restricted cell population propagates glioblastoma growth after chemotherapy","volume":"488","author":"Chen","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ctarc.2022.100537_bib0086","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/nature11344","article-title":"Defining the mode of tumour growth by clonal analysis","volume":"488","author":"Driessens","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ctarc.2022.100537_bib0087","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1126\/science.1224676","article-title":"Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas","volume":"337","author":"Schepers","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.ctarc.2022.100537_bib0088","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/1097-4644(20010601)81:3<535::AID-JCB1067>3.0.CO;2-6","article-title":"Baculovirus-expressed vitamin D-binding protein-macrophage activating factor (DBP-maf) activates osteoclasts and binding of 25-hydroxyvitamin D3 does not influence this activity","volume":"81","author":"Swamy","year":"2001","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ctarc.2022.100537_bib0089","doi-asserted-by":"crossref","first-page":"19122","DOI":"10.1038\/s41598-020-75571-y","article-title":"Simple method for large-scale production of macrophage activating factor GcMAF","volume":"10","author":"Nabeshima","year":"2020","journal-title":"Sci. Rep"},{"key":"10.1016\/j.ctarc.2022.100537_bib0090","first-page":"640","article-title":"Development of colostrum MAF and its clinical application","volume":"7","author":"Amitani","year":"2017","journal-title":"Neuropsychiatry (London)"},{"key":"10.1016\/j.ctarc.2022.100537_bib0091","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1073\/pnas.122126299","article-title":"Crystal structures of the vitamin D-binding protein and its complex with actin: Structural basis of the actin-scavenger system","volume":"99","author":"Otterbein","year":"2002","journal-title":"Proc. Natl. Acad. Sci. (USA)"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294222000284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294222000284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:37:17Z","timestamp":1762843037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294222000284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":91,"alternative-id":["S2468294222000284"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100537","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy with GcMAF revisited - A critical overview of the research of Nobuto Yamamoto","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100537","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100537"}}